Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer

Karim Fizazi, NamPhuong Tran, Luis Fein, +11

New England Journal of Medicine

Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial

Karim Fizazi, NamPhuong Tran, Luis Fein, +11

The Lancet Oncology

UrologyOncologyGenitourinary CancerAbiraterone AcetateCancer Management +4

Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study

Emmanuel S. Antonarakis, Josep M. Piulats, Marine Gross‐Goupil, +21

Journal of Clinical Oncology

Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer

Ronald de Wit, Johann S. de Bono, Cora N. Sternberg, +15

New England Journal of Medicine

Clinical Utility of the PCA3 Urine Assay in European Men Scheduled for Repeat Biopsy

Alexander Haese, Alexandre de la Taille, Hendrik Van Poppel, +11

European Urology

Urological ResearchUrologyGenitourinary CancerCancer DetectionClinical Utility +7

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Thomas Powles, Piotr Tomczak, Se Hoon Park, +226

The Lancet Oncology

Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1

Matthew R. Smith, Johann S. de Bono, Cora N. Sternberg, +23

Journal of Clinical Oncology

Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATITUDE Study

Nobuaki Matsubara, Kim N., Mustafa Özgüroğlu, +10

European Urology

UrologyGenitourinary CancerAbiraterone AcetateMedicineLatitude Study +6

Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe

Johann S. de Bono, Simon Chowdhury, Susan Feyerabend, +7

European Urology

Novel multi‐peptide vaccination in Hla‐A2+ hormone sensitive patients with biochemical relapse of prostate cancer

Susan Feyerabend, Stefan Stevanović, Cécile Gouttefangeas, +8

The Prostate